JBIO
Jade Biosciences, Inc.
$22.21
-1.25
(-5.33%)
Mkt Cap
724.62M
Volume
367,230
52W Range
6.565-28
Sector
Healthcare
Beta
1.52
EPS (TTM)
-2.92
P/E Ratio
-3.80
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (127.41M) | (69.63M) | (75.52M) | (51.51M) | (22.96M) | (9.61M) |
| EPS | -4.06 | -85.26 | -100.38 | -73.67 | -32.96 | -14.00 |
| Free Cash Flow | (94.89M) | (71.20M) | (56.92M) | (39.32M) | (27.58M) | (7.86M) |
| FCF / Share | -3.03 | -87.18 | -75.66 | -56.23 | -39.54 | -11.27 |
| Operating CF | (94.69M) | (71.20M) | (56.78M) | (39.12M) | (27.40M) | (7.86M) |
| Total Assets | 349.78M | 80.33M | 127.42M | 135.30M | 175.36M | 4.71M |
| Total Debt | 724,000 | 417,000 | 675,000 | 1.09M | 574,000 | 0 |
| Cash & Equiv | 88.44M | 33.75M | 23.49M | 22.40M | 54.20M | 4.57M |
| Book Value | 332.52M | 76.43M | 109.46M | 126.74M | 172.42M | 2.94M |
| Return on Equity | -0.38 | -0.91 | -0.69 | -0.41 | -0.13 | -3.27 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (40.37M) | (31.93M) | (25.18M) | (32.13M) | (2.52M) | (5.43M) | (16.28M) | (24.77M) | (23.19M) | (20.41M) | (19.56M) |
| EPS | -0.70 | -0.45 | -0.64 | -1.13 | -3.04 | -6.56 | -5.16 | -30.15 | -29.20 | -25.80 | -24.77 |
| Free Cash Flow | (24.08M) | (33.65M) | (22.18M) | (36.67M) | N/A | (11.05M) | 37.30M | (20.43M) | (23.67M) | (14.86M) | (15.64M) |
| FCF / Share | -0.42 | -0.48 | -0.56 | -1.29 | N/A | -13.34 | 11.82 | -24.87 | -29.81 | -18.78 | -19.81 |
| Operating CF | (24.08M) | (33.65M) | (22.12M) | (36.53M) | N/A | (11.05M) | 37.30M | (20.43M) | (23.67M) | (14.80M) | (15.61M) |
| Total Assets | 319.43M | 349.78M | 202.45M | 223.97M | 77.53M | 80.33M | 90.96M | 111.69M | 106.82M | 127.42M | 140.88M |
| Total Debt | 679,000 | 724,000 | 747,000 | 792,000 | 312,000 | 417,000 | 540,000 | 681,000 | 774,000 | 675,000 | 809,000 |
| Cash & Equiv | 55.09M | 88.44M | 50.11M | 220.94M | 44.22M | 33.75M | 31.11M | 31.07M | 9.12M | 23.49M | 32.18M |
| Book Value | 296.46M | 332.52M | 179.35M | 201.56M | 75.05M | 76.43M | 80.49M | 94.40M | 90.90M | 109.46M | 125.72M |
| Return on Equity | -0.14 | -0.10 | -0.14 | -0.16 | -0.03 | -0.07 | -0.20 | -0.26 | -0.26 | -0.19 | -0.16 |
JBIO News
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jade Biosciences Appoints Edward R. Conner, M.D.
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Jade Biosciences, Inc. (JBIO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Prepared Remarks Transcript
Jade Biosciences to Participate in Upcoming Conferences
Jade Biosciences, Inc. (JBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript